Copyright
©The Author(s) 2024.
World J Clin Cases. Jan 6, 2024; 12(1): 68-75
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.68
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.68
Table 1 General characteristics of the two groups
Group | Number of patients | Sex | Cause of disease | Age | ||
Male | Female | Chronic nephritis, nephrotic syndrome, renal tubulointerstitial disease | Others | |||
Observation group | 33 | 17 (51.51) | 16 (48.48) | 24 (72.72) | 9 (27.27) | 66.98 ± 6.45 |
Control group | 32 | 18 (56.25) | 14 (43.75) | 22 (68.75) | 10 (31.25) | 67.13 ± 6.13 |
χ2/t | - | 0.146 | 0.124 | 0.096 | ||
P value | - | 0.701 | 0.724 | 0.923 |
Table 2 Response rates in the two groups
Group | Number of patients | Significant | Effective | Ineffective | Total efficacy rate |
Observation group | 33 | 22 (66.66) | 9 (27.27) | 2 (6.06) | 31 (93.93) |
Control group | 32 | 7 (21.87) | 15 (46.87) | 10 (31.25) | 22 (68.75) |
χ2 | - | - | - | - | 6.847 |
P value | - | - | - | - | 0.008 |
Table 3 Coagulation status in the two groups
Group | Number of patients | Grade 0 | Grade I | Grade II | Grade III |
Observation group | 33 | 20 (60.60) | 5 (15.15) | 6 (18.18) | 2 (6.06) |
Control group | 32 | 5 (15.62) | 2 (6.06) | 14 (43.75) | 11 (34.37) |
χ2 | - | 13.887 | 1.339 | 0.498 | 8.140 |
P value | - | < 0.001 | 0.247 | 0.025 | 0.004 |
Table 4 Coagulation indices in the two groups
Group | PT (s) | APTT (s) | TT (s) | INR (s) | FIB (g/L) | |||||
Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |
Observation group (n = 33) | 16.25 ± 0.26 | 12.35 ± 0.56b | 40.12 ± 0.13 | 36.65 ± 0.23b | 21.48 ± 0.89 | 17.56 ± 0.48b | 2.31 ± 0.13 | 0.94 ± 0.05b | 6.17 ± 0.19 | 5.26 ± 0.11b |
Control group (n = 32) | 16.29 ± 0.33 | 15.48 ± 0.48b | 40.17 ± 0.19 | 39.48 ± 0.24b | 21.15 ± 0.78 | 20.03 ± 0.26b | 2.32 ± 0.19 | 2.01 ± 0.12b | 6.13 ± 0.56 | 3.26 ± 0.56b |
t | 0.543 | 24.160 | 1.241 | 48.544 | 1.587 | 25.680 | 0.248 | 47.181 | 0.388 | 20.124 |
P value | 0.588 | < 0.001 | 0.219 | < 0.001 | 0.117 | < 0.001 | 0.804 | < 0.001 | 0.699 | < 0.001 |
Table 5 Hemoglobin level and platelet count in the two treatment groups
Group | Number of patients | PLT count (× 109/L) | HGB level (g/L) | ||
Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | ||
Observation group | 33 | 41.23 ± 2.08 | 41.45 ± 2.56 | 96.58 ± 1.23 | 96.88 ± 1.11 |
Control group | 32 | 41.45 ± 1.98 | 41.88 ± 2.43 | 96.45 ± 1.08 | 96.78 ± 1.37 |
t | - | 0.436 | 0.694 | 0.452 | 0.323 |
P value | - | 0.664 | 0.490 | 0.652 | 0.747 |
Table 6 Adverse reactions after treatment in the two groups
Group | Number of patients | Autogenous hemorrhage | Rash | Fever | Untoward effect |
Observation group | 33 | 1 (3.03) | 0 (0.00) | 0 (0.00) | 1 (3.03) |
Control group | 32 | 6 (18.75) | 0 (0.00) | 1 (3.12) | 7 (21.87) |
χ2 | - | - | - | - | 5.345 |
P value | - | - | - | - | 0.027 |
- Citation: Liu K, Li ZH. Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. World J Clin Cases 2024; 12(1): 68-75
- URL: https://www.wjgnet.com/2307-8960/full/v12/i1/68.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i1.68